Country: United States
Language: English
Source: NLM (National Library of Medicine)
Risperidone (UNII: L6UH7ZF8HC) (Risperidone - UNII:L6UH7ZF8HC)
Ratiopharm Inc
Risperidone
Risperidone .25 mg
ORAL
PRESCRIPTION DRUG
Adults Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)] . Adolescents Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. Pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for Janssen Pharmaceuticals Corporation’s risperidone drug products. Monotherapy - Adults Risperidone tablets are indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in Adults [see Clinical Studies (14.2)] . Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. Pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for Janssen Pharmaceuticals Corporation’s risperido
Risperidone Tablets, 0.25 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n28 on the other and are available in: bottles of 100 NDC 58165-028-01 bottles of 500 NDC 58165-028-02 blisters (10 x 15 tablets cards) NDC 58165-028-03. Risperidone Tablets, 0.5 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n29 on the other and are available in: bottles of 100 NDC 58165-029-01 bottles of 500 NDC 58165-029-02 blisters (10 x 15 tablets cards) NDC 58165-029-03. Risperidone Tablets, 1 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n30 on the other and are available in: bottles of 100 NDC 58165-030-01 bottles of 500 NDC 58165-030-02 blisters (10 x 15 tablets cards) NDC 58165-030-03. Risperidone Tablets, 2 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n31 on the other and are available in: bottles of 100 NDC 58165-031-01 bottles of 500 NDC 58165-031-02 blisters (10 x 15 tablets cards) NDC 58165-031-03. Risperidone Tablets, 3 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n32 on the other and are available in: bottles of 100 NDC 58165-032-01 bottles of 500 NDC 58165-032-02 blisters (10 x 15 tablets cards) NDC 58165-032-03. Risperidone Tablets, 4 mg are supplied as oblong, biconvex, white, coated tablet, engraved rph on one side and n33 on the other and are available in: bottles of 100 NDC 58165-033-01 bottles of 500 NDC 58165-033-02 blisters (10 x 15 tablets cards) NDC 58165-033-03. Storage and Handling Risperidone Tablets should be stored at controlled room temperature 15°-25°C (59°-77°F). Protect from light and moisture. Keep out of reach of children.
Abbreviated New Drug Application
RISPERIDONE - RISPERIDONE TABLET, COATED RATIOPHARM INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RISPERIDONE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RISPERIDONE. RISPERIDONE TABLETS INITIAL U.S. APPROVAL 1993 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. RISPERIDONE TABLETS ARE NOT APPROVED FOR USE IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (5.1) RECENT MAJOR CHANGES _Boxed Warning_ _08/2008_ _Warnings and Precautions (_5.1_) 08/2008_ _Warnings and Precautions, Leucopenia, Neutropenia, and Agranulocytosis (_5.8_) 07/2009_ INDICATIONS AND USAGE Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults (1.1) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults (1.2) Treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years (1.3) _Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this product is not labeled for use in_ _pediatric patients with schizophrenia or bipolar mania. (_1.1_, _1.2_)_ DOSAGE AND ADMINISTRATION Initial Dose T itration Target Dose Effective Dose Range Schizophrenia-adults (2.1 ) 2 mg/day 1 to 2 mg daily 4 to 8 mg daily 4 to 16 mg/day Bipolar mania-adults (2.2 ) 2 to 3 mg /day 1mg daily 1 to 6mg /day 1 to 6 mg /day Irritability associated with autistic disorder (2.3 ) 0.25 mg/day (<20 kg) 0.5 mg/day (≥20 kg) 0.25 to 0.5 mg at ≥2 weeks 0.5 mg/day (<20 kg) 1 mg/day (≥20kg) 0.5 to 3 mg/day DOSAGE FORMS AND STRENGTHS Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg (3) CONTRAINDICATIONS Known hypersensitivity to the product (4) WARNINGS AND PRECAUTIONS Cerebrovascular Read the complete document